Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiotherapy versus temozolomide versus radiotherapy plus temozolomide in 1p/19q-codeleted anaplastic glioma
NL-OMON44004Phase 3Active, not recruiting
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Mar 2011
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of temozolomide in anaplastic oligodendroglioma (AO), oligoastrocytoma and anaplastic glioma (3 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Overall survival. Started Mar 2011; status: active, not recruiting.
02
Drugs
temozolomide
03
Conditions
anaplastic oligodendroglioma (AO)oligoastrocytomaanaplastic glioma
Beyond the preview
Go deeper on NL-OMON44004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44004.